A Study of BXQ-350 in Children With Newly Diagnosed Diffuse Intrinsic Pontine Glioma (DIPG) or Diffuse Midline Glioma (DMG) (KONQUER)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT04771897

Recruitment Status : Recruiting

First Posted : February 25, 2021

Last Update Posted : June 21, 2022

See Contacts and Locations

Sponsor:

Collaborator:

CTI Clinical Trial and Consulting Services

Information provided by (Responsible Party):

Bexion Pharmaceuticals, Inc.

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Recruitment Status :	Recruiting
Estimated Primary Completion Date :	October 2022
Estimated Study Completion Date :	October 2023

To Top